House Dust Mite Allergy – Pipeline Review, H2 2017

Global Markets Direct’s, ‘House Dust Mite Allergy – Pipeline Review, H2 2017’, provides an overview of the House Dust Mite Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for House Dust Mite Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for House Dust Mite Allergy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy

The report reviews pipeline therapeutics for House Dust Mite Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved House Dust Mite Allergy therapeutics and enlists all their major and minor projects

The report assesses House Dust Mite Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for House Dust Mite Allergy

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for House Dust Mite Allergy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding House Dust Mite Allergy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ALK-Abello A/S

Allergy Therapeutics Plc

Anergis SA

Biomay AG

Stallergenes Greer plc

Zhejiang I-Biological Technology Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

House Dust Mite Allergy - Overview

House Dust Mite Allergy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

House Dust Mite Allergy - Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

House Dust Mite Allergy - Companies Involved in Therapeutics Development

ALK-Abello A/S

Allergy Therapeutics Plc

Anergis SA

Biomay AG

Stallergenes Greer plc

Zhejiang I-Biological Technology Co Ltd

House Dust Mite Allergy - Drug Profiles

Acarovac Quattro - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AllerDM - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BM-35 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

house dust mite (Dermatophagoides farinae) allergen extract - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

House Dust Mite Allergy - Dormant Projects

House Dust Mite Allergy - Discontinued Products

House Dust Mite Allergy - Product Development Milestones

Featured News & Press Releases

May 04, 2017: ALK's HDM SLIT-tablet, ACARIZAX, approved in Canada

Apr 16, 2017: ACARIZAX approved in Europe for use in adolescent patients with house dust mite-induced allergic rhinitis

Mar 01, 2017: FDA approves Odactra for house dust mite allergies

Feb 14, 2017: Allergy Therapeutics Announces Novel House Dust Mite Allergy Vaccine Gains Clinical Trial Application Approval

Jan 27, 2017: Stallergenes Greer Announces Positive Top-Line Results Of Phase 3 Study For Pediatric House Dust Mite-Induced Allergic Rhinitis

Apr 27, 2016: Journal of the American Medical Association publishes Phase III data from allergic asthma trial with ALK house dust mite SLIT-tablet, ACARIZAX

Apr 13, 2016: License application for investigational house dust mite SLIT-tablet accepted for review by FDA

Apr 12, 2016: Merck Announces FDA Acceptance of Biologics License Application for Investigational House Dust Mite Sublingual Allergy Immunotherapy Tablet

Apr 05, 2016: Stallergenes Greer Announces The Approval Of Actair In Australia

Jan 27, 2016: Marketing authorisation for ACARIZAX issued in France

Dec 09, 2015: New product (ACARIZAX) for treatment of house dust mite allergic rhinitis and asthma obtains reimbursement in Denmark

Nov 26, 2015: New medicine for house dust mite allergic rhinitis now available in Japan

Nov 19, 2015: Desensitization Therapy Actair House Dust Mite Sublingual Tablets Launched in Japan

Sep 28, 2015: ALK’s partner, Torii, obtains approval for the house dust mite SLIT-tablet in Japan

Jun 09, 2015: ALK’s partner, MSD, publishes Phase II data on house dust mite SLIT-tablet in leading allergy journal

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for House Dust Mite Allergy, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

House Dust Mite Allergy – Pipeline by ALK-Abello A/S, H2 2017

House Dust Mite Allergy – Pipeline by Allergy Therapeutics Plc, H2 2017

House Dust Mite Allergy – Pipeline by Anergis SA, H2 2017

House Dust Mite Allergy – Pipeline by Biomay AG, H2 2017

House Dust Mite Allergy – Pipeline by Stallergenes Greer plc, H2 2017

House Dust Mite Allergy – Pipeline by Zhejiang I-Biological Technology Co Ltd, H2 2017

House Dust Mite Allergy – Dormant Projects, H2 2017

House Dust Mite Allergy – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for House Dust Mite Allergy, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports